|
gptkbp:instance_of
|
gptkb:biotechnology
gptkb:pharmaceuticals
|
|
gptkbp:acquisition
|
gptkb:Aclaris_Therapeutics
gptkb:Checkmate_Pharmaceuticals
|
|
gptkbp:annual_report
|
gptkb:Yes
|
|
gptkbp:awards
|
Multiple industry awards
|
|
gptkbp:biologics_license_application
|
gptkb:Yes
|
|
gptkbp:ceo
|
gptkb:Leonard_Schleifer
|
|
gptkbp:clinical_trial
|
gptkb:Yes
Worldwide
Published
ongoing
Phase 1
Phase 2
Phase 3
|
|
gptkbp:collaboration
|
gptkb:Astra_Zeneca
gptkb:Bayer_AG
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:community_engagement
|
gptkb:Yes
|
|
gptkbp:conducts_research_on
|
gptkb:George_Yancopoulos
|
|
gptkbp:employees
|
approximately 8,000
~2,500
|
|
gptkbp:fdaapprovals
|
gptkb:Multiple
|
|
gptkbp:financial_reports
|
gptkb:Yes
|
|
gptkbp:focus
|
gptkb:biotechnology
|
|
gptkbp:founded
|
gptkb:1988
|
|
gptkbp:founder
|
gptkb:Leonard_Schleifer
|
|
gptkbp:global_presence
|
gptkb:Yes
|
|
gptkbp:grants
|
gptkb:Yes
|
|
gptkbp:has_research_center
|
gptkb:Regeneron_Research_Center
|
|
gptkbp:headquarters
|
gptkb:Tarrytown,_New_York
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Regeneron Pharmaceuticals, Inc.
|
|
gptkbp:industry
|
gptkb:pharmaceuticals
|
|
gptkbp:instruction_set
|
Multiple candidates
|
|
gptkbp:invention
|
Numerous
|
|
gptkbp:investment
|
gptkb:Yes
Significant in R& D
|
|
gptkbp:investment_strategy
|
gptkb:Strong
|
|
gptkbp:leadership
|
Diverse executive team
|
|
gptkbp:location
|
gptkb:United_States
|
|
gptkbp:market_cap
|
$70 billion (2021)
$60 billion (2021)
|
|
gptkbp:notable_achievement
|
gptkb:Nobel_Prize_in_Physiology_or_Medicine_(2018)
COVID-19 treatment development
Developed first FDA-approved treatment for COVID-19
Developed Dupixent for asthma and eczema
Developed Eylea for eye diseases
|
|
gptkbp:notable_products
|
gptkb:Dupixent
gptkb:Regen-Cov
gptkb:Eylea
|
|
gptkbp:partnership
|
gptkb:Sanofi
|
|
gptkbp:partnerships
|
Academic institutions
|
|
gptkbp:philanthropy
|
gptkb:Regeneron_Foundation
|
|
gptkbp:products
|
gptkb:Dupixent
gptkb:Eylea
gptkb:Regen-COV
|
|
gptkbp:publications
|
Numerous
|
|
gptkbp:research_focus
|
monoclonal antibodies
Monoclonal antibodies
|
|
gptkbp:revenue
|
$8.5 billion (2020)
|
|
gptkbp:stock_symbol
|
gptkb:REGN
|
|
gptkbp:subsidiary
|
gptkb:Regeneron_Pharmaceuticals_Ireland_Ltd.
|
|
gptkbp:sustainability_initiatives
|
gptkb:Yes
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:website
|
www.regeneron.com
|
|
gptkbp:bfsParent
|
gptkb:NASDAQ
|
|
gptkbp:bfsLayer
|
4
|